Last $5.26 USD
Change Today -0.05 / -0.94%
Volume 25.9K
TRVN On Other Exchanges
Symbol
Exchange
NASDAQ GS
Berlin
As of 8:10 PM 03/3/15 All times are local (Market data is delayed by at least 15 minutes).

trevena inc (TRVN) Snapshot

Open
$5.28
Previous Close
$5.31
Day High
$5.36
Day Low
$5.25
52 Week High
03/5/14 - $9.95
52 Week Low
12/9/14 - $3.80
Market Cap
197.9M
Average Volume 10 Days
63.9K
EPS TTM
$-9.93
Shares Outstanding
37.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TREVENA INC (TRVN)

Related News

No related news articles were found.

trevena inc (TRVN) Related Businessweek News

No Related Businessweek News Found

trevena inc (TRVN) Details

Trevena, Inc., a clinical stage biopharmaceutical company, discovers, develops, and intends to commercialize therapeutics for G protein coupled receptors. The company is developing TRV027, which is in a Phase IIb clinical trial for the treatment of acute heart failure; TRV130, which has completed a Phase Ib clinical trial for the treatment of moderate to severe acute pain intravenously; and TRV734, which has completed a first Phase I clinical trial as an orally administered treatment for moderate to severe acute and chronic pain. Its small molecule delta-opioid receptor G protein biased ligand for the treatment of central nervous system disorders is in lead optimization. Trevena, Inc. was founded in 2007 and is based in King of Prussia, Pennsylvania.

32 Employees
Last Reported Date: 12/5/14
Founded in 2007

trevena inc (TRVN) Top Compensated Officers

Chief Executive Officer, President and Execut...
Total Annual Compensation: $532.6K
Chief Medical Officer
Total Annual Compensation: $376.5K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $441.4K
Compensation as of Fiscal Year 2013.

trevena inc (TRVN) Key Developments

Trevena, Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-03-2015 10:40 AM

Trevena, Inc. Presents at Cowen and Company 35th Annual Healthcare Conference, Mar-03-2015 10:40 AM. Venue: The Boston Marriott Copley Place, Boston, Massachusetts, United States. Speakers: Maxine Gowen, Chief Executive Officer, President and Executive Director.

Trevena Announces Positive Results from Phase 1 Multiple Ascending Dose Study of TRV734 for Moderate to Severe Acute and Chronic Pain

Trevena, Inc. announced positive data from a Phase 1 multiple ascending dose study of TRV734, a novel drug candidate in development as an orally administered treatment for moderate-to-severe acute and chronic pain. TRV734 showed pharmacokinetics, safety, tolerability, and CNS activity consistent with a previous Phase 1 study, and showed effectiveness similar to immediate-release oxycodone in an experimental pain model. This two-part trial evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of oral TRV734 in healthy males and females. In part A of the study, 125 mg TRV734 was given to 13 males following a high fat meal, a standard meal, and in three split portions following a fast via randomized cross-over design. Results showed that dosing paradigm did not affect TRV734 bioavailability. TRV734 in each dosing paradigm was associated with pupil constriction, a marker of CNS opioid activity, lasting approximately 4-6 hours, consistent with previous data. This suggests that TRV734 should have an appropriate duration of action for the treatment of acute pain when taken with or without food. The pharmacokinetics of different formulations of TRV734 will be evaluated further prior to commencing Phase 2 studies. In part B of the study, 62 male and female subjects fed standard meals were given placebo, 10 mg immediate-release oxycodone, or 60, 80, 125, or 175 mg of TRV734 every 6 hours for 24 hours. Pharmacokinetics after the first and last dose were similar. Trends in pupil constriction and increased tolerability of cold-induced pain after the first and last dose were noted for all doses of TRV734, with duration of approximately 4-6 hours. These effects were similar to that seen with 10 mg oxycodone. TRV734 was generally safe and well tolerated, and there were no serious or severe adverse events in either part of the study. Adverse events were generally opioid-related; the most common were somnolence, nausea, headache, dizziness, and vomiting, and were observed for both TRV734 and oxycodone. The Bowel Function Index (BFI), a validated tool to evaluate clinical constipation, was used to explore the potential for TRV734 to cause opioid-induced constipation and in this study showed encouraging trends compared to oxycodone. These data are consistent with preclinical data in which TRV734 produced less constipation than oxycodone at equianalgesic doses.

Trevena Appoints Anne Phillips as New Director

Trevena, Inc. has appointed Anne Phillips to its board of directors. Dr. Phillips replaces Farah Champsi, managing director at Alta Partners, who is stepping down from the Board following the Company's initial public offering earlier this year.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TRVN:US $5.26 USD -0.05

TRVN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TRVN.
View Industry Companies
 

Industry Analysis

TRVN

Industry Average

Valuation TRVN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TREVENA INC, please visit www.trevenainc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.